These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 23838676)

  • 41. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
    Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells.
    Odaka Y; Xu B; Luo Y; Shen T; Shang C; Wu Y; Zhou H; Huang S
    Carcinogenesis; 2014 Jan; 35(1):192-200. PubMed ID: 23929438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alkaline intracellular pH (pHi) increases PI3K activity to promote mTORC1 and mTORC2 signaling and function during growth factor limitation.
    Kazyken D; Lentz SI; Wadley M; Fingar DC
    J Biol Chem; 2023 Sep; 299(9):105097. PubMed ID: 37507012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
    Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
    Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
    Bommer UA; Iadevaia V; Chen J; Knoch B; Engel M; Proud CG
    Cell Signal; 2015 Aug; 27(8):1557-68. PubMed ID: 25936523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-18a promotes cell proliferation of esophageal squamous cell carcinoma cells by increasing cylin D1 via regulating PTEN-PI3K-AKT-mTOR signaling axis.
    Zhang W; Lei C; Fan J; Wang J
    Biochem Biophys Res Commun; 2016 Aug; 477(1):144-149. PubMed ID: 27291152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
    PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.